UNSPSC 51271706: Phenacaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C18H22N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B61HM98KO, chemically known as n,n(sup 2)-bis(p-ethoxyphenyl)acetamidine but more generally known as phenacaine hydrochloride, which bears US NIH Compound Identifier 7588. Most nations, for tariff and trade purposes, schedule phenacaine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, PHENACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Phenacaine hydrochloride bears US NLM identifiers UMLS ID C0770375 and NCI Concept Code C75099. SMILES: CCOC1CCC(CC1)N/C(=N/C2CCC(CC2)OCC)/C.O.CL.

UNSPSC 51271706 Phenacaine hydrochloride is a Commodity code encompassing local anesthetic pharmaceutical products supplied to state and local government healthcare facilities through cooperative purchasing agreements. State and local governments procure phenacaine hydrochloride and related generic pharmaceuticals primarily through multistate cooperative purchasing alliances that consolidate demand across participating jurisdictions and establish master supply agreements with manufacturers and authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent solicitation activity, sourcing generic pharmaceuticals for distribution across state and local healthcare systems in multiple states including Minnesota and Oregon. Issuing bodies under this code are cooperative purchasing organizations that serve state departments, local health agencies, and other government facilities rather than individual jurisdictions bidding independently.

The Minnesota Department of Administration's Office of State Procurement issued MMCAP's Request for Proposal S1070000015802 on January 20, 2026, with proposals due March 26, 2026, seeking manufacturers to supply generic multi-source pharmaceuticals and over-the-counter products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). Evaluation emphasizes price competitiveness (75 percent of scoring), with secondary weight on fixed pricing (10 percent), compliance with data format requirements and EDI capability (5 percent each), and acceptance of a 3 percent administrative fee (5 percent). Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence and network security liability of $2,000,000. The two-year contract term begins July 1, 2026, with products requiring marketplace availability by May 15, 2026, and minimum six-month shelf life from manufacture.